Skip to main content
SpringerLink
Log in

Platelets and Polymorphisms

  • Chapter
  • First Online:
Platelets, Haemostasis and Inflammation

Part of the book series: Cardiac and Vascular Biology ((Abbreviated title: Card. vasc. biol.,volume 5))

  • 930 Accesses

Abstract

Functional genome-wide association studies and pharmacogenomics of antiplatelet therapy are of high clinical interest to explain the interindividual variability of drug response. Here, we review recent progress in knowledge of platelet genomics with focus on clinical implications. While there are numerous genetic variants associated with platelet biology with focus on platelet-specific phenotypes and cardiovascular outcome, the clinical evidence is missing so far. However, platelet pharmacogenomics concentrating on antiplatelet drug metabolism and transport is already used in personalized medicine.

Supported by the Deutsche Forschungsgemeinschaft KFO 274 (SCHW 858/1-2) and in part by the Robert-Bosch-Stiftung (Stuttgart, Germany).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007 Dec 13;357(24):2482–94.

    PubMed  Google Scholar 

  2. Müller KA, Chatterjee M, Rath D, Geisler T. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD. Thromb Haemost. 2015;114(3):498–518.

    PubMed  Google Scholar 

  3. O’Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, Myers RH, D'Agostino RA, Levy D, Tofler GH. Framingham heart study genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation. 2001;103(25):3051–6.

    PubMed  Google Scholar 

  4. Bray PF, Mathias RA, Faraday N, Yanek LR, Fallin MD, Herrera-Galeano JE, Wilson AF, Becker LC, Becker DM. Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost. 2007;5(8):1617–23.

    CAS  PubMed  Google Scholar 

  5. Johnson AD, Yanek LR, Chen M-H, et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet. 2010;42:608–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Kunicki TJ, Nugent DJ. The genetics of normal platelet reactivity. Blood. 2010;116(15):2627–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Geisler T, Schaeffeler E, Gawaz M, Schwab M. Genetic variation of platelet function and pharmacology: an update of current knowledge. Thromb Haemost. 2013;110(5):876–87.

    CAS  PubMed  Google Scholar 

  8. Jones CI, Bray S, Garner SF, Stephens J, de Bono B, Angenent WG, Bentley D, Burns P, Coffey A, Deloukas P, Earthrowl M, Farndale RW, Hoylaerts MF, Koch K, Rankin A, Rice CM, Rogers J, Samani NJ, Steward M, Walker A, Watkins NA, Akkerman JW, Dudbridge F, Goodall AH, Ouwehand WH, Bloodomics Consortium. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood. 2009;114(7):1405–16.

    CAS  PubMed  Google Scholar 

  9. Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, Catanese J, Young BA, Reitsma PH, Devlin JJ, Rosendaal FR. Gene variants associated with deep vein thrombosis. JAMA. 2008 Mar 19;299(11):1306–14. https://doi.org/10.1001/jama.299.11.1306

    Article  CAS  PubMed  Google Scholar 

  10. Snoep JD, Gaussem P, Eikenboom JC, Emmerich J, Zwaginga JJ, Holmes CE, Vos HL, de Groot PG, Herrington DM, Bray PF, Rosendaal FR, van der Bom JG. The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE-Platelets project. J Thromb Haemost. 2010;8(11):2377–84.

    CAS  PubMed  Google Scholar 

  11. Faraday N, Yanek LR, Yang XP, Mathias R, Herrera-Galeano JE, Suktitipat B, Qayyum R, Johnson AD, Chen MH, Tofler GH, Ruczinski I, Friedman AD, Gylfason A, Thorsteinsdottir U, Bray PF, O’Donnell CJ, Becker DM, Becker LC. Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood. 2011 Sep 22;118(12):3367–75. https://doi.org/10.1182/blood-2010-11-320788

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Meisinger C, Prokisch H, Gieger C, et al. A genome-wide association study identifies three loci associated with mean platelet volume. Am J Hum Genet. 2009;84(1):66–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Soranzo N, Spector TD, Mangino M, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet. 2009;41(11):1182–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Sajid M, Vijayan KV, Souza S, Bray PF. PlA polymorphism of integrin beta 3 differentially modulates cellular migration on extra-cellular matrix proteins. Arterioscler Thromb Vasc Biol. 2002;22:1984–9.

    CAS  PubMed  Google Scholar 

  15. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Platelet GPIIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation. 2000;101:1013–8.

    CAS  PubMed  Google Scholar 

  16. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090–4.

    CAS  PubMed  Google Scholar 

  17. Gieger C, Radhakrishnan A, Cvejic A, Tang W, Porcu E, Pistis G, Serbanovic-Canic J, Elling U, Goodall AH, Labrune Y, Lopez LM, Mägi R, Meacham S, Okada Y, Pirastu N, Sorice R, Teumer A, Voss K, Zhang W, Ramirez-Solis R, Bis JC, Ellinghaus D, Gögele M, Hottenga JJ, Langenberg C, Kovacs P, O’Reilly PF, Shin SY, Esko T, Hartiala J, Kanoni S, Murgia F, Parsa A, Stephens J, van der Harst P, Ellen van der Schoot C, Allayee H, Attwood A, Balkau B, Bastardot F, Basu S, Baumeister SE, Biino G, Bomba L, Bonnefond A, Cambien F, Chambers JC, Cucca F, D’Adamo P, Davies G, de Boer RA, de Geus EJ, Döring A, Elliott P, Erdmann J, Evans DM, Falchi M, Feng W, Folsom AR, Frazer IH, Gibson QD, Glazer NL, Hammond C, Hartikainen AL, Heckbert SR, Hengstenberg C, Hersch M, Illig T, Loos RJ, Jolley J, Khaw KT, Kühnel B, Kyrtsonis MC, Lagou V, Lloyd-Jones H, Lumley T, Mangino M, Maschio A, Mateo Leach I, McKnight B, Memari Y, Mitchell BD, Montgomery GW, Nakamura Y, Nauck M, Navis G, Nöthlings U, Nolte IM, Porteous DJ, Pouta A, Pramstaller PP, Pullat J, Ring SM, Rotter JI, Ruggiero D, Ruokonen A, Sala C, Samani NJ, Sambrook J, Schlessinger D, Schreiber S, Schunkert H, Scott J, Smith NL, Snieder H, Starr JM, Stumvoll M, Takahashi A, Tang WH, Taylor K, Tenesa A, Lay Thein S, Tönjes A, Uda M, Ulivi S, van Veldhuisen DJ, Visscher PM, Völker U, Wichmann HE, Wiggins KL, Willemsen G, Yang TP, Hua Zhao J, Zitting P, Bradley JR, Dedoussis GV, Gasparini P, Hazen SL, Metspalu A, Pirastu M, Shuldiner AR, Joost van Pelt L, Zwaginga JJ, Boomsma DI, Deary IJ, Franke A, Froguel P, Ganesh SK, Jarvelin MR, Martin NG, Meisinger C, Psaty BM, Spector TD, Wareham NJ, Akkerman JW, Ciullo M, Deloukas P, Greinacher A, Jupe S, Kamatani N, Khadake J, Kooner JS, Penninger J, Prokopenko I, Stemple D, Toniolo D, Wernisch L, Sanna S, Hicks AA, Rendon A, Ferreira MA, Ouwehand WH, Soranzo N. New gene functions in megakaryopoiesis and platelet formation. Nature. 2011;480(7376):201–8. https://doi.org/10.1038/nature10659

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet. 2011;43(4):339–44.

    Google Scholar 

  19. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buysschaert I, Cardiogenics, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, PP MK, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Mühleisen TW, Muhlestein JB, Münzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nöthen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schäfer A, Schillert A, Schreiber S, Schrezenmeir J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoep JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Witteman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, März W, Hengstenberg C, Blankenberg S, Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O’Donnell CJ, McPherson R, Erdmann J, CARDIoGRAM Consortium, Samani NJ. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43(4):333–8. https://doi.org/10.1038/ng.784

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Sl N, Shaw C, Kong X, Kondkar AA, Edelstein LC, Ma L, Chen J, McKnight GS, López JA, Yang L, Jin Y, Bray MS, Leal SM, Dong JF, Bray PF. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood. 2011;117(19):5189–97.

    Google Scholar 

  21. Kaudewitz D, Skroblin P, Bender LH, Barwari T, Willeit P, Pechlaner R, Sunderland NP, Willeit K, Morton A, Armstrong PC, Chan MV, Lu R, Yin X, Gracio F, Dudek K, Langley S, Zampetaki A, de Rinaldis E, Ye S, Warner TD, Saxena A, Kiechl S, Storey R, Mayr M. Association of microRNAs and YRNAs with platelet function. Circ Res. 2015 Dec 8. https://doi.org/10.1161/CIRCRESAHA.114.305663

    CAS  PubMed  Google Scholar 

  22. McManus DD, Freedman JE. MicroRNAs in platelet function and cardiovascular disease. Nat Rev Cardiol. 2015;12(12):711–7.

    CAS  PubMed  Google Scholar 

  23. Simon LM, Edelstein LC, Nagalla S, Woodley AB, Chen ES, Kong X, Ma L, Fortina P, Kunapuli S, Holinstat M, McKenzie SE, Dong JF, Shaw CA, Bray PF. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood. 2014;123(16):e37–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Meyer UA, Zanger UM, Schwab M. Omics and drug response. Annu Rev Pharmacol Toxicol. 2013;53:475–502.

    CAS  PubMed  Google Scholar 

  25. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015 Oct 15;526(7573):343–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Schwab M, Schaeffeler E. Pharmacogenomics: a key component of personalized therapy. Genome Med. 2012;4(11):93.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, Zuern C, Moerike K, Gawaz M, Schwab M. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. 2008 Sep;9(9):1251–9.

    CAS  PubMed  Google Scholar 

  28. Simon T, Verstuyft C, Mary-Krause M, et al. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–75.

    CAS  PubMed  Google Scholar 

  29. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 genetic polymorphisms and the response to clopidogrel. N Engl J Med. 2009;360:354–62.

    CAS  PubMed  Google Scholar 

  30. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309–17.

    CAS  PubMed  Google Scholar 

  31. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K, Morath T, Schömig A, Kastrati A, von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30(8):916–22.

    CAS  PubMed  Google Scholar 

  32. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009;103(6):806–11.

    CAS  PubMed  Google Scholar 

  33. Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–57.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Cayla G, Hulot JS, O’Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignalou JB, Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthélémy O, Montalescot G, Collet JP. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;306(16):1765–74.

    CAS  PubMed  Google Scholar 

  35. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, Cayla G, Beygui F, Montalescot G. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56(2):134–43.

    CAS  PubMed  Google Scholar 

  36. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010 Oct 27;304(16):1821–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 2011 Jun;11(3):199–206.

    CAS  PubMed  Google Scholar 

  38. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306(24):2704–14.

    CAS  PubMed  Google Scholar 

  39. Jin B, Ni HC, Shen W, Li J, Shi HM, Li Y. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep. 2011;38(3):1697–702.

    CAS  PubMed  Google Scholar 

  40. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ. 2011;343:d4588.

    PubMed  PubMed Central  Google Scholar 

  41. Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart. 2012;98(2):100–8.

    CAS  PubMed  Google Scholar 

  42. Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Seol SH, Kim DI, Kim BH, Park YH, Je HG, Jeong YH, Lee SW. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol. 2012;110(4):502–8.

    CAS  PubMed  Google Scholar 

  43. Yamaguchi Y, Abe T, Sato Y, Matsubara Y, Moriki T, Murata M. Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis. Platelets. 2013;24(5):352–61.

    CAS  PubMed  Google Scholar 

  44. Singh M, Shah T, Adigopula S, Molnar J, Ahmed A, Khosla S, Arora R. CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful? Indian Heart J. 2012;64(4):341–52.

    PubMed  PubMed Central  Google Scholar 

  45. Lewis JP, Stephens SH, Horenstein RB, O’Connell JR, Ryan K, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Mitchell BD, Shuldiner AR. The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost. 2013;11(9):1640–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Frére C, Cuisset T, Gaborit B, Alessi MC, Hulot JS. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost. 2009;7(8):1409–11.

    PubMed  Google Scholar 

  47. Li Y, Tang HL, Hu YF, Xie HG. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost. 2012;10(2):199–206.

    CAS  PubMed  Google Scholar 

  48. Reny JL, Combescure C, Daali Y, Fontana P, PON1 Meta-Analysis Group. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost. 2012 July;10(7):1242–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Tarkiainen EK, Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M. Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin Pharmacol Ther. 2015;97(6):650–8.

    CAS  PubMed  Google Scholar 

  50. Lewis JP, Horenstein RB, Ryan K, O’Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Gurbel PA, Shuldiner AR. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013;23(1):1–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010 Oct 16;376(9749):1312–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Luo M, Li J, Xu X, Sun X, Sheng W. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis. Thromb Res. 2012;129(6):754–9.

    CAS  PubMed  Google Scholar 

  53. Su J, Xu J, Li X, Zhang H, Hu J, Fang R, Chen X. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One. 2012;7(10):e46366.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007 Dec;5(12):2429–36.

    CAS  PubMed  Google Scholar 

  55. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009 May 19;119(19):2553–60.

    CAS  PubMed  Google Scholar 

  56. Franken CC, Kaiser AF, Krüger JC, Overbeck K, Mügge A, Neubauer H. Cytochrome P450 2B6 and 2C9 genotype polymorphism—a possible cause of prasugrel low responsiveness. Thromb Haemost. 2013;110(1):131–40.

    CAS  PubMed  Google Scholar 

  57. Cuisset T, Loosveld M, Morange PE, Quilici J, Moro PJ, Saut N, Gaborit B, Castelli C, Beguin S, Grosdidier C, Fourcade L, Bonnet JL, Alessi MC. CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc Interv. 2012;5(12):1280–7.

    PubMed  Google Scholar 

  58. Xiang Q, Cui Y, Zhao X, Zhao N. Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics. Pharmacogenomics. 2013;14(10):1179–89.

    CAS  PubMed  Google Scholar 

  59. Varenhorst C, Eriksson N, Johansson Å, Barratt BJ, Hagström E, Åkerblom A, Syvänen AC, Becker RC, James SK, Katus HA, Husted S, Steg PG, Siegbahn A, Voora D, Teng R, Storey RF, Wallentin L, PLATO Investigators. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015;36(29):1901–12.

    CAS  PubMed  Google Scholar 

  60. Moßhammer D, Schaeffeler E, Schwab M, Mörike K. Mechanisms and assessment of statin-related muscular adverse effects. Br J Clin Pharmacol. 2014 Sep;78(3):454–66.

    PubMed  PubMed Central  Google Scholar 

  61. Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, Schwab M, Schaeffeler E. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 2013;5(1):1.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41.

    CAS  PubMed  Google Scholar 

  63. Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 2012;22(2):159–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart. 2012 Jan;98(2):100–8.

    CAS  PubMed  Google Scholar 

  65. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR, Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Schwab M, Schaeffeler E. Warfarin pharmacogenetics meets clinical use. Blood. 2011 Sep 15;118(11):2938–9.

    CAS  PubMed  Google Scholar 

  67. Droppa M, Tschernow D, Müller KA, Tavlaki E, Karathanos A, Stimpfle F, Schaeffeler E, Schwab M, Tolios A, Siller-Matula JM, Gawaz M, Geisler T. Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). PLoS One. 2015 Mar 23;10(3):e0121620.

    PubMed  PubMed Central  Google Scholar 

  68. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DY. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012 May 5;379(9827):1705–11.

    CAS  PubMed  Google Scholar 

  69. Stimpfle F, Karathanos A, Droppa M, Metzger J, Rath D, Müller K, Tavlaki E, Schäffeler E, Winter S, Schwab M, Gawaz M, Geisler T. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. Thromb Res. 2014;134(1):105–10.

    CAS  PubMed  Google Scholar 

  70. Shuldiner AR, Palmer K, Pakyz RE, Alestock TD, Maloney KA, O’Neill C, Bhatty S, Schub J, Overby CL, Horenstein RB, Pollin TI, Kelemen MD, Beitelshees AL, Robinson SW, Blitzer MG, McArdle PF, Brown L, Jeng LJ, Zhao RY, Ambulos N, Vesely MR. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):76–84.

    PubMed  Google Scholar 

  71. Tarkiainen EK, Backman JT, Neuvonen M, Neuvonen PJ, Schwab M, Niemi M. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther. 2012 Jul;92(1):68–71.

    CAS  PubMed  Google Scholar 

  72. Zakim D, Schwab M. Data collection as a barrier to personalized medicine. Trends Pharmacol Sci. 2015;36(2):68–71.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstraße 112, 70376, Stuttgart, Germany

    Tobias Geisler, Elke Schaeffeler & Matthias Schwab

  2. University of Tübingen, Tübingen, Germany

    Tobias Geisler, Elke Schaeffeler & Matthias Schwab

  3. Department of Clinical Pharmacology, University Hospital Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Germany

    Matthias Schwab

  4. Department of Pharmacy and Biochemistry, University of Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Germany

    Matthias Schwab

Authors
  1. Tobias Geisler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elke Schaeffeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Schwab
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Schwab .

Editor information

Editors and Affiliations

  1. Cardiology and Angiology I, University-Heart Center Freiburg, Freiburg, Germany

    Andreas Zirlik

  2. Cardiology and Angiology I, University-Heart Center Freiburg, Freiburg, Germany

    Christoph Bode

  3. Department of Cardiology, University Hospital Tübingen, Tübingen, Germany

    Meinrad Gawaz

Compliance with Ethical Standards

Compliance with Ethical Standards

  • Conflict of Interest: Tobias Geisler, Elke Schaeffeler, and Matthias Schwab declares that they have no conflict of interest.

  • Ethical Approval: This article contains studies with human participants or animals performed by the authors with ethical approval.

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Geisler, T., Schaeffeler, E., Schwab, M. (2017). Platelets and Polymorphisms. In: Zirlik, A., Bode, C., Gawaz, M. (eds) Platelets, Haemostasis and Inflammation. Cardiac and Vascular Biology, vol 5. Springer, Cham. https://doi.org/10.1007/978-3-319-66224-4_17

Download citation

Publish with us

Policies and ethics

Search

Navigation